Friday, October 23, 2015

08:30-10:00
Session 2: Industry Symposium                                                                                                         Hall A

Controversies in bone health
Supported by Amgen Oncology
 

Session not included in main CME/CPD program 
08:30-10:00
Session 3: Controversies in screening and imaging                                                                     Hall B
Chairpersons

Christobel Saunders, Australia
Gelareh Farshid, Australia
08:30-09:30
Breast screening: Retain it, scrap it or reform it?

Population based mammographic screening has resulted in improved breast cancer outcomes
Bruce Mann, Australia
Population based mammographic screening has not delivered on its promise
Robert Burton, Australia
The future is tailored screening
John Hopper, Australia
Discussion

 

09:30-10:00
Debate: MRI for local staging: Essential tool or an unnecessary luxury?
Essential tool: Jane O’Brien, Australia
Unnecessary luxury: David Speakman, Australia
Discussion
 
10:00-10:30 Coffee break and poster viewing
10:30-11:30
Session 4: Molecular profiling in early breast cancer:                                                               Hall A
An important addition, or is a good pathologist enough?
Chairpersons

Richard De Boer, Australia
Shane White, Australia

10:30

Adjuvant chemotherapy in ER+ve/her2-ve breast cancer
Shane White, Australia
10:40 Case presentations (with audience voting)
10:50-11:25
Debate: That molecular profiling improves decision-making in early stage breast cancer
Yes: Eva Segelov, Australia
No: Stephen Fox, Australia
Rebuttal and Discussion
 
11:25 Cases represented  
10:30-11:30
Session 5: Free Communication Session                                                                                       Hall B
Chairpersons

Michael Green, Australia
Prue Francis, Australia

10:30

Refining the breast cancer molecular subtypes in the metabric data set
Heloisa Helena Milioli, Australia
10:40

Effect of neo adjuvant chemotherapy on hormone receptor status of breast cancer: A meta analysis
Seenu Vuthaluru, India
10:50 

Patient preferences for adjuvant radiotherapy - outcomes from the targIt: A study in Western Australia
Tammy Corica, Australia
11:00

Should breast cancer screening programs routinely measure mammographic density?
Jennifer Stone, Australia
11:10

The prognostic value of 18F-fluorodeoxyglucose (18f-fdg) pet/ct-detected internal
mammary nodal involvement in patients with locally advanced breast cancer
Steven David, Australia 
11:20

Novel blood biomarkers as the basis of a breast cancer screening test
Dharmica Mistry, Australia 
11:30-13:00
Session 6: Industry Symposium                                                                                                        Hall A

Controversies in Her2-positive disease                               
Supported by Roche Oncology  
 

Session not included in main CME/CPD program 
   
11:30-13:00
Session 7: Breast Care Nurses:                                                                                                         Hall B
Care coordinators or agents of lifestyle change?
Chairpersons

Kerry Shanahan, Australia
Lisa Sheeran, Australia

11:30

Opening speaker:
Lifestyle change as cancer therapy: What is the evidence; is it for everyone?
Sandra Hayes , Australia
11:50-12:20
Debate: That BCNs have a role and responsibility to provide education on the importance of exercise and weight control after breast cancer
Central role: Melanie Fisher, Australia
No role: Kim Kerin-Ayres, Australia 
 
12:20 Panel Discussion, led by Julie Bissinella, Australia 
Meron Pitcher, Australia
Melanie Fisher, Australia
Kim Kerin-Ayres, Australia
Sandra Hayes, Australia
Christine Mitchell, Australia
13:00-14:00 Lunch break and poster viewing
14:00-15:30
Session 8: Controversies in adjuvant chemotherapy                                                            Hall A
Chairpersons

Nicole McCarthy, Australia
Elgene Lim, Australia

14:00-14:35
Debate: That all TNBC patients should receive a platinum agent in the adjuvant setting
Yes: Catherine Oakman, Australia
No: Louis Chow, Spain
Discussion 
 
14:35-15:10
Debate: That bone targeted agents should be a standard of care in post-menopausal early stage breast cancer
Yes: Jodi Lynch, Australia
No: Nicholas Wilcken, Australia 
Discussion
 
15:10 Adjuvant chemotherapy in the old/frail patient: How do I approach this?
Christopher Steer, Australia   
14:00-15:30
Session 9: Controversies in  breast conservation:                                                                    Hall B
Better surgery, better pathology, better radiotherapy?
Chairpersons

Andrew Spillane, Australia
Steven David, Australia

14:00-14:30
Debate: That parenchymal preservation is more important than oncoplastic technique 
Yes: Jane Fox, Australia
No: James French, Australia
Discussion
 
14:30-15:00
Debate: That size (of margins) still matters
Yes: Christopher Pyke, Australia
No: Raghu Ram, India
Discussion
 
15:00-15:30
Debate: That intraoperative radiotherapy is ready for prime time
Yes: Christobel Saunders, Australia
No: Abram Recht, USA
Discussion
15:30-16:00 Coffee break and poster viewing
16:00-17:30
Session 10: Controversies in loco-regional management                                                          Hall A
Chairpersons

Christopher Pyke, Australia
Claire Phillips, Australia

16:00-16:30
Debate: That hypofractionated, short course radiation is the gold standard in all patients undergoing whole breast RT after local excision of breast cancer or DCIS
Yes: Steven David, Australia
No: Susan Pendlebury, Australia
Discussion
 
16:30-17:00
Debate: That ACOSOG Z11 is a practice changing study
Yes: Alastair Thompson, USA
No: Ian Campbell, New Zealand
Discussion
 
17:00-17:30
Debate: That regional nodal radiotherapy should be considered in all patients with early stage node positive breast cancer
Yes:Mario Guerrieri, Australia
No: Abram Recht, USA
Discussion